COMPREHENSIVE ANALYSIS OF DNA COPY NUMBER VARIATIONS

1. COMPREHENSIVE ANALYSIS OF DNA COPY NUMBER VARIATIONS AND GENE EXPRESSION IN OSTEOSARCOMA Nalan Gokgoz, Atta Goudarzi, Cheryl Wolting Jay S. Wunder and Irene L. Andrulis Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital Toronto, ON, Canada. Connective Tissue Oncology Society Meeting November 1, 2013

2. Identification and Characterization of Molecular Alterations in Osteosarcoma High resolution approaches to identify genes and pathways predictive of outcome in OS • Gene expression profiling byMicroarray Analysis • Interrogation of biological pathways and networks • Identification of the most relevant biological pathways for list of discriminative genesbyIngenuity Pathway Analysis • Identification of the significant effectors and organizing networks in OS metastasis by Dynamo (Taylor and Chuang) • Investigation of Copy Number Changes byIllumina SNP array technology • Detection and characterization of alterations • Analysis and visualization by Genome Studio and GAP • Identification of significant recurrent targets by GISTIC

3. High-grade Intramedullary 63 patients No Metastasis at Diagnosis 46 patients Metastasis at Diagnosis 17 patients No Metastasis 4 years post Dx. (29 patients) Metastasis within 4 years Dx. (17 patients) PATIENT COHORT A B A1 A2

4. MICROARRAY ANALYSIS No Metastases 4 years post Dx (A1)vs Metastases within 4 years Dx (A2) Outcome of the Patients Presenting with “no Metastases” No Mets. 4 yrs post Dx. Mets. within 4 yrs post Dx. 18981 cDNAs T-statistic p<0.001 (BrB Array Tools) n=53 genes for tumor classification/clustering Statistical validation by Leave-One Out cross-validation method Molecular validation by Real-Time Analysis

5. UpstreamRegulators Ingenuity Pathway Analysis Upstream regulators that may be responsible for observed increase/decrease in expression Molecule Set Networks Pathways Gene A Gene C . . Gene X Gene Y Interactions and Relationships between molecules in set Pathways with which molecules in set are associated Functions with which molecules in set are associated Functions

6. Summary of IPA in OS metastasis Networks cell morphology, organization, hematopoiesis Pathways Rac/Rho, actin cytoskeleton Functions hematopoiesis, cell movement Regulators Fas, Fos, SP1, SREBF1

7. Signaling by Rho Family GTPases A1 – No mets A2 – Mets in 4 yrs Lower expression in A2 Higher expression in A2

8. GENETIC NETWORKS in OS METASTASIS • Significant Networks • Transport • Translation • Signaling • The PRKCε, RASGPR3 and GNB2 networks differentially activated • DLG2 network differentially organized • The PRKCε, RASGPR3 and GNB2 networks are potential effectors of DLG2 Protein Kinase C Epsilon and Genetic Networks in Osteosarcoma Metastasis; A Goudarzi, N Gokgoz, M Gill, D Pinnaduwage, D. Merico, J.S Wunder and IL Andrulis, Cancer, 2013, 5, 372-403

9. Osteosarcoma and Copy Number Alterations Illumina 610-Quad Whole-genome genotyping beadchip Coverage includes >14,000 CNV regions and 550K evenly spaced TagSNPs from HapMap data High Resolution: Spacing 2.7 kb Includes markers in the unSPNable Genome Allows detection of SNPs, Copy Number Variation and Genotype Reference Genotype: Canonical genotype clusters (200 HapMap DNA genotype data) 44 Osteosarcoma Tumor DNA • 25 of them with matched blood DNA • Validation by Real Time PCR

10. Complexity of OS Tumour Genome (Analysis by Genome Studio) Allele Frequency BB AB AA Blood DNA LogR Ratio Tumour DNA

11. Genome Alteration Print (GAP) Analysis OS-2550_Chromosome 3

12. Recurrent Copy Number Gains in OS identified by GISTIC (Genome Identification of Significant Targets in Cancer) * • CDK4 • MDM2 • COPS3 • NCORI • PMP22 • COL12A1 • COL9A1 • AF086303 • COL4A1 • COL4A2 • LIG4 • MYR8 • PPFIBP1 • FGFR1OP2 * * q value *Same family genes

13. Recurrent Copy Number Losses in OS identified by GISTIC * * * • DOCK5 • CDKN2A • MTAP NAALADL2 • RB1 • LOC285194 • GRIK2 • CNTNAP2 • DLG2 • TP53 q value *Same family genes

14. 11q14.1 deletion in a matched tumor-blood DNA DLG2

15. Implication of DLG2 as a tumour suppressor in cancer • One of the most disorganized genetic networks in metastatic OS tumours. • The PRKCε, RASGPR3 and GNB2 networks are potential effectors of DLG2 • Tumour suppressor function of dlg2 in Drosophila • Scribble complex (SCRIB, DLG1-4 and LGL1/2) deregulation in Prostate Cancer • DLG2 implicated in Wilms Tumour

16. DLG2 (discs, large homolog 2) • Channel associated protein of synapse 110 • Chromosome 11q14 • Member of the membrane-associated guanylate kinase (MAGUK) family. • PDZ domains; interaction with signalling proteins at postsynaptic sites • SH3 domains are found in proteins of signaling pathways regulating the cytoskeleton and regulate the activity state of adaptor proteins and other tyrosine kinases • GuKinase Domain; catalyzes ATP-dependent phosphorylation of GMP to GDP • Gene: 2 MB, 33 alternative spliced transcripts • Longest transcript :3.7KB, 26 Exons • Expression site: Brain, hypothalamus

17. Relative Expression of DLG2 in OS tumours and cell-lines Deletion of DLG2 gene detected by SNP array

18. Work in Progress • SiRNA Knockdown of the DLG2 Gene in U2OS • 70% knockdown at 72 hours • The effect of DLG2 knockdown in • Cell viability and growth by XTT assay • Migration by scratch assay • Sequencing of DLG2 gene for inactivating mutations

19. CONCLUSION • We identified a 53-gene expression signature that may predict outcome • of OS patients with localized tumours. • High-resolution approaches identified candidate pathways and networks that may be biologically relevant in OS. • Cell morphology and organization pathways may be involved in OS metastasis. • A large number of chromosomal aberrations were detected in OS tumours by SNP array technology. • The DLG2 gene that is deleted in 20 percent of the OS cases and belonging to a significantly disorganized metastatic OS network and was chosen for further functional analysis. • Further experiments will be performed to investigate the functional role of DLG2 in cell growth, proliferation and migration.

20. Acknowledgement Andrew Seto S.Bull R. Parkes I. Andrulis J. Wunder Andrulis and Wunder Lab R. Kandel University of Washington E.Conrad III Mount Sinai Hospital Orthopedic Surgeons Royal Orthopedic Hospital R.Grimer Hospital for Sick Children D.Malkin Memorial Sloan-Kettering J.Healey Vancouver General Hospital C.Beauchamp Mayo Clinic M.Rock/ L.Wold

21. During progression from tumour growth to metastasis, specific integrin signals enable cancer cells to detach from neighbouring cells, re-orientate their polarity during migration, and survive and proliferate in foreign microenvironments. There is increasing evidence that certain integrins associate with receptor tyrosine kinases (RTKs) to activate signalling pathways that are necessary for tumour invasion and metastasis. The effect of these integrins might be especially important in cancer cells that have activating mutations, or amplifications, of the genes that encode these RTKs.